Home › Upcoming votes › Processa Pharmaceuticals, Inc.
This meeting took place on July 30, 2026. Processa Pharmaceuticals, Inc. reported the official results on Form 8-K, filed August 4, 2026 (read it on EDGAR); they are listed below.
The deadline as the proxy statement states it: “Proxies submitted by telephone or through the internet must be received by 11:59 p.m. EDT on July 29, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGAR
As listed in Processa Pharmaceuticals, Inc.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | Election of Directors Director election |
Board | For | — |
| 2 | To approve an amendment and restatement of the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan | Board | For | — |
| 3 | Ratification of the Appointment of the Independent Registered Public Accounting Firm Audit Committee Report Auditor |
Board | For | 96% support |
| 4 | Advisory Approval of Named Executive Officer Compensation Say on pay |
Board | For | 88% support |
From Processa Pharmaceuticals, Inc.’s Form 8-K, filed July 18, 2025, for the meeting held July 18, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Justin Yorke | — | — |
| Elect Director: George Ng | — | — |
| Elect Director: Khoso Baluch | — | — |
| Elect Director: James Neal | — | — |
| Elect Director: Geraldine Pannu | — | — |
| Elect Director: Dr, David Young | — | — |
| 2. The issuance of shares of common stock upon exercise of the Series A and B Warrants sold pursuant to the Securities Purchase Agreements e | 86% | Approved |
| 3. The appointment of Cherry Bekaert, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025 | 96% | Approved |
| 4. The advisory vote relating to compensation of our named executive officers | 88% | Approved |
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Justin Yorke | — | — |
| Elect Director: George Ng | — | — |
| Elect Director: Khoso Baluch | — | — |
| Elect Director: James Neal | — | — |
| Elect Director: Geraldine Pannu | — | — |
| Elect Director: Dr, David Young | — | — |
| 2. The amendment and restatement of the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan to increase the number of shares availabl | 79% | Approved |
| 3. The appointment of Cherry Bekaert, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 | 99.1% | Approved |
| 4. The advisory vote relating to compensation of our named executive officers | 88% | Approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the filing automatically and checked against the proxy’s own item count and voting card; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.